1. (Currently Amended) ~~Compounds~~ A compound having the structure of Formula I:



Formula - I

and ~~their~~ its pharmaceutically acceptable salt ~~salts~~, pharmaceutically acceptable enantiomer, diastereomer ~~solvates, esters, enantiomers, diastereomers~~, or N-oxide ~~N-oxides~~, ~~polymorphs, or metabolites,~~ wherein

Ar represents an aryl ~~or a heteroaryl~~ ring ~~having 1-2 hetero atoms, the aryl or heteroaryl rings~~ which may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C_1-C_4), lower perhalo alkyl (C_1-C_4), cyano, hydroxy, nitro, lower alkoxy (C_1-C_4), lower perhalo alkoxy (C_1-C_4), unsubstituted amino, N-lower alkyl (C_1-C_4) or -aryl amino, amino carbonyl, or N-lower alkyl (C_1-C_4) or -aryl amino carbonyl;

R_1 represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen;

R_2 represents alkyl, C_3-C_7 cycloalkyl ring, a C_3-C_7 cyclo alkenyl ring, an aryl, heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl, heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C_1-C_4), lower perhalo alkyl (C_1-C_4), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C_1-C_4), lower perhalo alkoxy (C_1-C_4), unsubstituted amino, N-lower alkyl (C_1-C_4) or –aryl amino, amino carbonyl, or N-lower alkyl (C_1-C_4) or –aryl amino carbonyl;

W represents $(CH_2)_p$, wherein p represents 0 to 1;

X represents ~~an oxygen, sulphur, -NR or~~ no atom~~, wherein R represents hydrogen or (C1-6) alkyl~~;

Y represents ~~CHR5CO or~~ $(CH_2)q$ wherein ~~R5 represents hydrogen or methyl and~~ q represents 0 ~~to 4~~;

Z represents oxygen, sulphur, or NR_{10}, wherein R_{10} represents hydrogen or C_{1-6} alkyl;

Q represents $-(CH_2)_n-$, wherein n represents 0 to 4, CHR_8, wherein R_8 represents H, OH, C_{1-6}, alkyl, C_{1-6} alkenyl, or C_{1-6} alkoxy, or Q represents CH_2CHR_9, wherein R_9 represents H, OH, lower alkyl (C_1-C_4) or lower alkoxy (C_1-C_4); and

R_6 and R_7 are independently selected from H, CH_3, COOH, $CONH_2$, NH_2, and CH_2NH_2.

2. (Currently Amended) The ~~compounds~~ compound according to claim 1 having the structure of Formula II and ~~their~~ its pharmaceutically acceptable salt ~~salts~~, pharmaceutically acceptable enantiomer, diastereomer or N-oxide ~~solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.~~



Formula II

3. (Currently Amended) The ~~compounds~~ compound according to claim 1 having the structure of Formula III and ~~their~~ its pharmaceutically acceptable salt ~~salts~~, pharmaceutically acceptable enantiomer, diastereomer or N-oxide ~~solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.~~



Formula III

4. (Currently Amended) The ~~compounds~~ compound according to claim 1 having the structure of Formula IV and ~~their~~ its pharmaceutically acceptable salt ~~salts~~, pharmaceutically acceptable enantiomer, diastereomer or N-oxide ~~solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites~~, wherein r is 1 to 4.



Formula IV

5. (Currently Amended) The ~~compounds~~ compound according to claim 1 having the structure of Formula V, and ~~their~~ its pharmaceutically acceptable salt ~~salts~~, pharmaceutically acceptable enantiomer, diastereomer or N-oxide ~~solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites~~, wherein s represents 1 to 2.



Formula V

6. (Currently Amended) A compound selected from ~~form~~ the group consisting of

(2R,2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound 1);

(2R,2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 2);

(2R)-(1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compound 3);

(2R)-(1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 4);

(2S)-(1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide (Compound 5);

(2S)-(1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-phenyl acetamide hydrochloride salt (Compound 6);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide (Compound 7);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Compound 8);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound 9);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide tartarate salt (Compound 10);

(2R) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound 11);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide (Compound 12);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound 13);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound 14);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound 15);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound 16);

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound 17) and

(2R, 2S) (1α,5α,6α)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl)-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide (Compound 18).

7. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1, 2, 3, 4, 5 or 6 together with a pharmaceutically acceptable carrier, excipient or diluent ~~carriers, excipients or diluents~~.

8.- 26. (Cancelled)